Protalix BioTherapeutics, Inc - רווח למניה ב-12 החודשים האחרונים PLX

Protalix BioTherapeutics (PLX) ensures the uninterrupted supply of medical centers through verified global couriers. The company generates revenue from Gaucher disease therapies reimbursed by the government and insurers. This chart of the company's price action reflects an EPS (TTM) of 267.70. The business's technological foundation is built upon the unique ProCellEx plant-based protein synthesis system, which guarantees the issuer's status as a bioengineering leader.

Year-over-year EPS growth (TTM) reflects the dynamics of net income per share over a rolling twelve-month period. This measurement of annual TTM EPS growth allows for an assessment of the scaling speed of the business's fundamental value. The metric is calculated by comparing current earnings with the same interval from the previous year, eliminating seasonal distortions. For Protalix BioTherapeutics (PLX), such indicators are critical, as the proprietary ProCellEx platform must convert its technological advantage into real financial results despite stringent FDA oversight.